CardiolRx™
Recurrent Pericarditis
Key Facts
About Cardiol Therapeutics
Cardiol Therapeutics is a focused, clinical-stage biotechnology company dedicated to developing innovative treatments for heart disease. Its core strategy leverages the anti-inflammatory and anti-fibrotic properties of a proprietary, pharmaceutical-grade cannabidiol (CBD) formulation, CardiolRx™, currently in two Phase II trials for inflammatory cardiac conditions. The company aims to address substantial unmet medical needs in cardiology through a targeted, scientifically-driven approach, supported by public market financing.
View full company profileAbout Cardiol Therapeutics
Cardiol Therapeutics is a focused, clinical-stage biotechnology company dedicated to developing innovative treatments for heart disease. Its core strategy leverages the anti-inflammatory and anti-fibrotic properties of a proprietary, pharmaceutical-grade cannabidiol (CBD) formulation, CardiolRx™, currently in two Phase II trials for inflammatory cardiac conditions. The company aims to address substantial unmet medical needs in cardiology through a targeted, scientifically-driven approach, supported by public market financing.
View full company profileTherapeutic Areas
Other Recurrent Pericarditis Drugs
| Drug | Company | Phase |
|---|---|---|
| ARCALYST (rilonacept) | Kiniksa Pharmaceuticals | Commercial |
| KPL-387 | Kiniksa Pharmaceuticals | Phase 2/3 |